Vemlidy Warnings

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Warnings

POST TREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B: Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted [see Severe Acute Exacerbation of Hepatitis B after Discontinuation of Treatment under Precautions].

tenofovir alafenamide

Manufacturer:

Gilead Sciences

Distributor:

DCH Auriga - Healthcare